Masakazu Toi M.D. Ph.D Professor
For Japanese females, the incidence of breast cancer is the highest amongst all cancers. The incidence and mortality rate of breast cancer are rising every year. In our research group, studies ranging from molecular biological research to clinical trials are performed with the aim of generating new diagnostic, therapeutic and preventive tools. Furthermore, studies of the treatment personalization according to an individual’s risk profile are being initiated to create a next generation breast cancer medical platform.
Research and EducationIn order to realize the personalized medicine in breast cancer treatment, genomic, epigenetic and transcriptomic profiles of breast cancer are being analyzed. Furthermore, host reactions to breast cancers, including immune and inflammatory responses, are investigated using biomaterials from breast cancer patients. Therefore, a variety of translational researches as well as biomarker development are activated in this laboratory.
Currently, several types of new diagnostic technologies are under development in our laboratory, including photo-acoustic technologies for imaging of tumor vasculature and its function, imaging mass spectrometry technologies to identify next generation biomarkers for early detection of breast cancer, and microRNA profiling system and algorithm to predict treatment response of breast cancer. In parallel, studies to create a new approach for the prevention of breast cancer are being initiated according to a concept of life cycle care of life style.
Many innovative investigators are engaged in creating new ideas for understanding of breast cancer and the development of novel preventive, diagnostic and therapeutic tools for breast cancer patients.
Recent Publications1.Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):74-84.
2.Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer.Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3.
3.Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells Cancer Metab. 2020 Jul 6;8:13. doi: 10.1186/s40170-020-00219-4. eCollection 2020.
4.Kawaguchi K, Sakurai M, Yamamoto Y, Suzuki E, Tsuda M, Kataoka TR, Hirata M, Nishie M, Nojiri T, Kumazoe M, Saito K, Toi M. Alteration of specific cytokine expression patterns in patients with breast cancer.Sci Rep. 2019 Feb 27;9(1):2924. doi: 10.1038/s41598-019-39476-9.
5.Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. Visualising peripheral arterioles andvenules through high-resolution and large-area photoacoustic imaging. Sci Rep. 2018 Oct 8;8(1):14930.
Breast SurgeryProfessor： Masakazu Toi
Associate professor： Masahiro Takada
Assistant Professor： Masahiro Kawashima, Kosuke Kawaguchi, Ayane Yamaguchi
Program-Specific Hospital Assistant Professor： Nobuko Kawaguchi
Program-Specific Assistant Professor： Yoshiaki Matsumoto
Clinical Fellow： Yuki Iwano, Akihiro Umejima, Kana Kawanishi, Marin Taguchi